Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025)
Inhibikase Therapeutics (IKT) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $23688.0 in Q3 2025.
- On a quarterly basis, Depreciation & Amortization (CF) rose 260.66% to $23688.0 in Q3 2025 year-over-year; TTM through Mar 2026 was $47845.0, a 47.86% increase, with the full-year FY2025 number at $60499.0, up 130.28% from a year prior.
- Depreciation & Amortization (CF) reached $23688.0 in Q3 2025 per IKT's latest filing, down from $24157.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for IKT hit a ceiling of $159204.0 in Q2 2023 and a floor of $1681.0 in Q3 2022.
- A 4-year average of $20836.7 and a median of $6568.0 in 2023 define the central range for Depreciation & Amortization (CF).
- Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 290.72% in 2023, then tumbled 95.87% in 2024.
- Tracing IKT's Depreciation & Amortization (CF) over 4 years: stood at $5042.0 in 2022, then soared by 30.27% to $6568.0 in 2023, then fell by 0.02% to $6567.0 in 2024, then skyrocketed by 260.71% to $23688.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for IKT at $23688.0 in Q3 2025, $24157.0 in Q2 2025, and $12654.0 in Q1 2025.